Recent evidence from series of small renal mass biopsy samples and methodologically robust meta-analyses provides improved guidance on cost–benefit trade-offs for diagnosis and management of this disease. Renal mass biopsy sampling should be reserved for situations in which it will affect management decisions – which it will not do for all patients.
- Hiten D. Patel
- Phillip M. Pierorazio
